Researchers Discover First Clues on How Gut Health Influences Brain Health – Technology Networks

New cellular and molecular processes underlying communication between gut microbes and brain cells have been described for the first time by scientists at Weill Cornell Medicine and Cornells Ithaca campus.

Over the last two decades, scientists have observed a clear link between autoimmune disorders and a variety of psychiatric conditions. For example, people with autoimmune disorders such as inflammatory bowel disease (IBD), psoriasis and multiple sclerosis may also have depleted gut microbiota and experience anxiety, depression and mood disorders. Genetic risks for autoimmune disorders and psychiatric disorders also appear to be closely related. But precisely how gut health affects brain health has been unknown.

Our study provides new insight into the mechanisms of how the gut and brain communicate at the molecular level, said co-senior author Dr. David Artis, director of the Jill Roberts Institute for Research in Inflammatory Bowel Disease, director of the Friedman Center for Nutrition and Inflammation and the Michael Kors Professor of Immunology at Weill Cornell Medicine. No one yet has understood how IBD and other chronic gastrointestinal conditions influence behavior and mental health. Our study is the beginning of a new way to understand the whole picture.

For the study, published in Nature, the researchers used mouse models to learn about the changes that occur in brain cells when gut microbiota are depleted. First author Dr. Coco Chu, a postdoctoral associate in the Jill Roberts Institute for Research in Inflammatory Bowel Disease, led a multidisciplinary team of investigators from several departments across Weill Cornell Medicine, Cornells Ithaca campus, the Boyce Thompson Institute, Broad Institute at MIT and Harvard, and Northwell Health with specialized expertise in behavior, advanced gene sequencing techniques and the analysis of small molecules within cells.

Mice treated with antibiotics to reduce their microbial populations, or that were bred to be germ-free, showed a significantly reduced ability to learn that a threatening danger was no longer present. To understand the molecular basis of this result, the scientists sequenced RNA in immune cells called microglia that reside in the brain and discovered that altered gene expression in these cells plays a role in remodeling how brain cells connect during learning processes. These changes were not found in microglia of healthy mice.

Changes in gene expression in microglia could disrupt the pruning of synapses, the connections between brain cells, interfering with the normal formation of new connections that should occur through learning, said co-principal investigator Dr. Conor Liston, an associate professor of neuroscience in the Feil Family Brain & Mind Research Institute and an associate professor of psychiatry at Weill Cornell Medicine.

The team also looked into chemical changes in the brains of germ-free mice and found that concentrations of several metabolites associated with human neuropsychiatric disorders such as schizophrenia and autism were changed. Brain chemistry essentially determines how we feel and respond to our environment, and evidence is building that chemicals derived from gut microbes play a major role, said Dr. Frank Schroeder, a professor of chemistry and chemical biology at Cornell and at the Boyce Thompson Institute.

Next, the researchers tried to reverse the learning problems in the mice by restoring their gut microbiota at various ages from birth. We were surprised that we could rescue learning deficits in germ-free mice, but only if we intervened right after birth, suggesting that gut microbiota signals are required very early in life, said Dr. Liston. This was an interesting finding, given that many psychiatric conditions that are associated with autoimmune disease are associated with problems during early brain development.

The gut-brain axis impacts every single human being, every day of their lives, said Dr. Artis. We are beginning to understand more about how the gut influences diseases as diverse as autism, Parkinsons disease, post-traumatic stress disorder and depression. Our study provides a new piece of understanding of how the mechanisms operate.

We dont know yet, but down the road, there is a potential for identifying promising targets that might be used as treatments for humans in the future, Dr. Liston said. Thats something we will need to test going forward.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the article here:

Researchers Discover First Clues on How Gut Health Influences Brain Health - Technology Networks

Foreign aid leader’s visit focuses on UW partnership opportunities – University of Wisconsin-Madison

Im a Badger, says Mark Green (left), walking toward the Stock Pavilion, and when I look at everything this fantastic university is doing, I say, the sky is the limit. Photo by Rodee Schneider

As a Wisconsin native and UW alumnus, USAID Administrator Mark Green understands better than most the breadth of expertise that exists on the University of WisconsinMadison campus. He saw it as a law student, as a state representative and later as a member of congress representing Wisconsins 8th district.

Green visits the lab of Tony Goldberg, an epidemiology professor in the School of Veterinary Medicine whose research focuses on global health and infectious disease. Photo by Rodee Schneider

On Oct. 18, Greens knowledge of UWMadisons academic range brought him to campus for a discussion about potential partnership opportunities between USAID and the university. Green has held the top post at USAID the United States foreign aid and development since 2017.

I cant think of any USAID interests where UW doesnt have a subject matter expert, said Green. The issues where we have questions, you have answers.

The agency frequently works with top U.S. universities on issues related to hunger and agriculture, economic development, education, global health and more.

Green, who also served as the U.S. ambassador to Tanzania from 2007 to 2009, spent the day on campus meeting with faculty, university administrators and researchers. His morning included a discussion with a group of campus leaders working on international issues, a visit with Chancellor Rebecca Blank, and a trip to the laboratory of TonyGoldbergin the School ofVeterinary Medicine to learn about global health and international studies in infectious disease.

PhD student Leah Owens, who is doing research in Goldbergs lab on molecular diagnostics of wildlife disease, shows Green components of their lab in a box, which is designed as a mobile field lab. Photo by Rodee Schneider

For USAID, the visit represents a broader effort to expand its partner base and tap into universities regional and technical knowledge and research expertise.

For UWMadison, the meeting offered a chance to explore new opportunities for mutually beneficial collaborations with USAID, potentially extending the reach and impact of work already occurring on campus.

We have a long history of research related to USAID interests, said Nancy Kendall, an associate professor of educational policy studies, who was part of a committee exploring opportunities for partnership with USAID. We want to see the Wisconsin Idea shared with the world.

Greens visit included a discussion with a group of campus leaders working on international issues. Photo by Rodee Schneider

While Greens global work exposes him to some of the planets biggest challenges, including hunger, natural disaster and political turmoil, given what hes seen from university partners, hes hopeful for the future.

One of the reasons Im really optimistic is your students. Theyre coming up with designs and innovation we never considered, said Green.

Im a Badger, and when I look at everything this fantastic university is doing, I say, the sky is the limit.

Share via Facebook

Share via Twitter

Share via Linked In

Share via Email

Read more:

Foreign aid leader's visit focuses on UW partnership opportunities - University of Wisconsin-Madison

Genome sequencing data to help in predictive and preventive medicine – Down To Earth Magazine

Minister Harsh Vardhan claims project will help in cost-effective, precision medicine

Research laboratories working under the Council of Scientific and Industrial Research (CSIR) on Friday announced completion of whole genome sequencing of 1008 Indian individuals representing diverse ethnic groups in the country. The data will act as baseline information for developing various applications in predictive and preventive medicine.

The genomic data will help scientists understand genetic diversity of the Indian population and make available genetic variant frequencies for clinical applications. The data and knowhow are expected to produce evidence and help in development of technologies for clinical and biomedical applications, scientists explained.

The project called IndiGen was implemented by Delhi-based Institute of Genomics and Integrative Biology (IGIB) and Hyderabad-based Centre for Cellular and Molecular Biology (CCMB). The whole genome sequencing of individuals drawn from across the country has been completed, enabling benchmarking the scalability of genome sequencing and computational analysis at population scale, Union Minster for Science and Technology Harsh Vardhan said.

The genome data will be important for building the knowhow, baseline data and indigenous capacity in the emerging area of precision medicine, he said. The outcomes of the IndiGen will find applications in a number of areas, including faster and efficient diagnosis of rare genetic diseases, he added.

It will further lead to cost-effective genetic tests, carrier screening applications for expectant couples, enabling efficient diagnosis of heritable cancers and pharmacogenetic tests to prevent adverse drug reactions are some of the other benefits of this initiative.

Scientists have also developed IndiGenome card and mobile application for researchers and clinicians to access clinically actionable information. The minister said it would ensure privacy and data security, which is vital for personal genomics to be implemented at large scale.

CSIR has been engaged in genomic studies in India and its Indian Genome Variation has made major contributions in understanding genetic makeup of Indian population. It has also pioneered the application of genomics in clinical settings in the area of rare genetic diseases by means of DNA and genome based diagnostics and interaction with large number of clinical collaborators. (India Science Wire)

We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.

Link:

Genome sequencing data to help in predictive and preventive medicine - Down To Earth Magazine

Bulls-Eye: Imaging Technology Could Confirm When a Drug Is Going to the Right Place – On Cancer – Memorial Sloan Kettering

Summary

Doctors and scientists from Memorial Sloan Kettering report on an innovative technique for noninvasively watching where a targeted therapy is going in the body. It also allows them to see how much of the drugreaches the tumor.

Targeted therapy has become an important player in the collection of treatments for cancer. But sometimes its difficult for doctors to determine whether a persons tumor has the right target or how much of a drug is actually reaching it.

A multidisciplinary team of doctors and scientists from Memorial Sloan Kettering has discovered an innovative technique for noninvasively visualizing where a targeted therapy is going in the body. This method can also measure how much of it reaches the tumor. What makes this development even more exciting is that the drug they are studying employs an entirely new approach for stopping cancer growth. The work was published on October 24 in Cancer Cell.

This paper reports on the culmination of almost 15 years of research, says first author Naga Vara Kishore Pillarsetty, a radiochemist in the Department of Radiology. Everything about this drug from the concept to the clinical trials was developed completely in-house at MSK.

Our research represents a new role for the field of radiology in drug development, adds senior author Mark Dunphy, a nuclear medicine doctor. Its also a new way to provide precision oncology.

Our research represents a new role for the field of radiology in drug development.

The drug being studied, called PU-H71, was developed by the studys co-senior author Gabriela Chiosis. Dr. Chiosis is a member of the Chemical Biology Program in the Sloan Kettering Institute. PU-H71 is being evaluated in clinical trials for breast cancer and lymphoma, and the early results are promising.

We always hear about how DNA and RNA control a cells fate, Dr. Pillarsetty says. But ultimately it is proteins that carry out the functions that lead to cancer. Our drug is targeting a unique network of proteins that allow cancer cells to thrive.

Most targeted therapies affect individual proteins. In contrast, PU-H71 targets something called the epichaperome. Discovered and named by Dr. Chiosis, the epichaperome is a communal network of proteins called chaperones.

Chaperone proteins help direct and coordinate activities in cells that are crucial to life, such as protein folding and assembly. The epichaperome, on the other hand, does not fold. It reorganizes the function of protein networks in cancer, which enables cancer cells to survive under stress.

Previous research from Dr. Chiosis and Monica Guzman of Weill Cornell Medicine provided details on how PU-H71 works. The drug targets a protein called the heat shock protein 90 (HSP90). When PU-H71 binds to HSP90 in normal cells, it rapidly exits. But when HSP90 is incorporated into the epichaperome, the PU-H71 molecule becomes lodged and exits more slowly. This phenomenon is called kinetic selectivity. It helps explain why the drug affects the epichaperome. It also explains why PU-H71 appears to have fewer side effects than other drugs aimed at HSP90.

At the same time, this means that PU-H71 works only in tumors where an epichaperome has formed. This circumstanceled to the need for a diagnostic method to determine which tumors carry the epichaperome and, ultimately, who might benefit from PU-H71.

Communal Behavior within Cells Makes Cancers Easier to Target

Findings about proteins called molecular chaperones are shedding new light on possible approaches to cancer treatment.

In the Cancer Cell paper, the investigators report the development of a precision medicine tactic that uses a PET tracer with radioactive iodine. It is called [124I]-PU-H71 or PU-PET. PU-PET is the same molecule as PU-H71 except that it carries radioactive iodine instead of nonradioactive iodine. The radioactive version binds selectively to HSP90 within the epichaperome in the same way that the regular drug does. Ona PET scan, PU-PET displays the location of the tumor or tumors that carry the epichaperome and therefore are likely to respond to the drug. Additionally, when its given along with PU-H71, PU-PET can confirm that the drug is reaching the tumor.

This research fits into an area that is sometimes called theranostics or pharmacometrics, Dr. Dunphy says. We have found a very different way of selecting patients for targeted therapy.

He explains that with traditional targeted therapies, a portion of a tumor is removed with a biopsy and then analyzed. Biopsies can be difficult to perform if the tumor is located deep in the body. Additionally, people with advanced disease that has spread to other parts of the body may have many tumors, and not all of them may be driven by the same proteins. By using this imaging tool, we can noninvasively identify all the tumors that are likely to respond to the drug, and we can do it in a way that is much easier for patients, Dr. Dunphy says.

The researchers explain that this type of imaging also allows them to determine the best dose for each person. For other targeted therapies, doctors look at how long a drug stays in the blood. But that doesnt tell you how much is getting to the tumor, Dr. Pillarsetty says. By using this imaging agent, we can actually quantify how much of the drug will reach the tumor and how long it will stay there.

Plans for further clinical trials of PU-H71 are in the works. In addition, the technology reported in this paper may be applicable for similar drugs that also target the epichaperome.

Go here to see the original:

Bulls-Eye: Imaging Technology Could Confirm When a Drug Is Going to the Right Place - On Cancer - Memorial Sloan Kettering

Repairing the brain through stem cell therapy – Monash Lens

Theres a new frontier in medicine that seeks to cure not just treat symptoms by regenerating healthy tissue destroyed by disease.

In the firing line are currently incurable diseases that impose enormous suffering, debilitation and costs. This includes the muscle wasting inflicted by muscular dystrophy, for example, or the loss of brain neural cells in the case of Parkinsons disease.

Its the latter that the startup Convalesce Inc is primarily targeting, based on the development of a self-assembling and self-repairing material called AmGel. It contains nanofibres capable of nurturing stem cells to replace damaged nerves a function that can make or break the use of stem cells therapeutically.

To get all the interacting factors right meant drawing on nanotechnology, bioengineering, cell biology, developmental biology and material science super-advanced stuff.

AmGels development and commercialisation, however, owes a great deal to a new model for producing the next generation of innovators in this case, Convalesces co-founder, Dr Subhadeep Das.

He graduated with a PhD in 2017 from an academy specifically established to use advanced multidisciplinary research techniques to address critical global challenges, including in energy, infrastructure and manufacturing. Called the IITB-Monash Research Academy, its a joint venture between the Indian Institute of Technology Bombay (IITB) and Monash University.

Speaking from the prestigious IndieBio accelerator program in San Francisco, Das explains that stem cell technology perfectly fits the academys mission. These are cells that are potentially game-changing for medicine, yet their use is held back by the cells complex relationship to its molecular, cellular and extra-cellular environment.

You cant just inject stem cells into inflamed and damaged tissue. They dont survive in that micro environment, Das says. The solution requires drawing on multiple disciplines like having smaller pieces for a jigsaw puzzle.

For Parkinsons disease, that involves understanding the biophysicality of the brain and the dimensions and topography of its subcellular structures. This has led to the designing of nanofibres that form a scaffold for stem cells to attach and grow into. This matrix also cues stem cell growth and development into functioning nerve cells.

To get all the interacting factors right meant drawing on nanotechnology, bioengineering, cell biology, developmental biology and material science super-advanced stuff, Das says.

The science, however, is just the first step towards a cure. Convalesce constitutes the second phase meeting the testing, regulatory and commercialisation hurdles needed to get a viable therapy to patients.

Das admits the learning curve has been steep in the segue from research to commercialisation. Working alone, he might not have succeeded.

Instead, he took advantage of ongoing support provided by the IITB-Monash Research Academy, including the provision of exclusive rights to the intellectual property for AmGel, and mentoring from across both universities, especially from the academys CEO, Professor Murali Sastry.

He discovered that while starting a company is tough, there are people who are willing to help if you reach out. Its making the connections in the first place that matters.

On that score, the Monash alumni office do a great job. They provided us with introductions to alumni that included highly successful entrepreneurs and heads of venture firms. These are people who are willing to help because of the connection with Monash University.

View post:

Repairing the brain through stem cell therapy - Monash Lens

AI Pinpoints Genes Associated With Heart Failure – Forbes

While AI may increase speed and efficiency of medical care on the front lines, one of its most powerful benefits is the ability to search vast amounts of data to learn about genetic aspects of various diseases.

Cardiomegaly Is An Enlargement Of The Heart Due To Dilatation Of The Heart Cavities. This Can Result ... [+] From Many Conditions Including A Disease Of The Heart Muscle Myocardial Disease, Defective Valve Function, Or Hypertrophy Of The Heart Muscle Due To Stenosis Of The Aortic Valve. Pericardial Effusion Fluid Collection In The Fibrous Envelope Of The Heart Can Also Lead To Considerable Cardiomegaly Visible On The X Ray. Left Untreated, Cardiomegaly Can Lead To Heart Failure Characterized By Dyspnea Difficulty Breathing And Edema Of The Lower Limbs. (Photo By BSIP/UIG Via Getty Images)

Earlier identification of persons at risk for heart failure or a genetic cardiomyopathy is a prime example. This could enable persons to be more closely monitored by health care providers and even placed on lists for transplant before they decompensate and develop heart failure leading to cardiogenic shock, which can be ultimately be fatal if not treated and identified in a timely fashion.

Researchers at Queen Mary University of London have now harnessed the power of AI to identify patients who are at risk for heart failure, enabling earlier identification, management and treatment of these high-risk individuals.

The research team used an artificial intelligence (AI) technique to analyze cardiac MRI images of 17,000 healthy UK Biobank volunteers. They noted that genetic factors accounted for 22-39% of variation in the size and function of the left ventricle (LV), the main chamber in the heart that pumps blood to the rest of the body. Reduced pumping ability and increase in size of the left ventricle leads to heart failure.

The research, recently published in the journalCirculation, highlights the importance of genetic factors and their role in the contribution to structural heart disease. The investigators discovered 14 specific areas (loci) linked to the dimensions, structure and function of the left ventricle containing genes that control the embryonic development of heart chambers and the contraction of heart muscle.

"It is exciting that the state-of-the-art AI techniques now allow rapid and accurate measurement of the tens of thousands of heart MRI images required for genetic studies, said lead researcher Dr. Nay Aung from Queen Mary University of London in a press release. The findings open up the possibility of earlier identification of those at risk of heart failure and of new targeted treatments; the genetic risk scores established from this study could be tested in future studies to create an integrated and personalized risk assessment tool for heart failure.

"The AI tool allowed us to analyze images in a fraction of the time it would otherwise have taken; this should translate to time and cost savings for the NHS and could potentially improve the efficiency of patient care, he added.

"Previous studies have shown that differences in the size and function of the heart are partly influenced by genes but we have not really understood the extent of that genetic influence,explained co-investigator Steffen Petersen, Professor of Cardiovascular Medicine at Queen Mary University of London. This study has shown that several genes known to be important in heart failure also appear to regulate the heart size and function in healthy people.

That understanding of the genetic basis of heart structure and function in the general population improves our knowledge of how heart failure evolves; the study provides a blueprint for future genetic research involving the heart MRI images in the UK Biobank and beyond, he added.

"High fidelity MRI measures combined with genetics is reassuringly validating many known heart structural proteins, but our work also finds new genes from more heritable functional measures that are associated with ventricular remodeling and fibrosis, added co-investigator Patricia Munroe, Professor of Molecular Medicine at Queen Mary University of London. Further genetic studies including analyses of additional heart MRI chambers are expected to provide deeper insights into heart biology."

In fact, identification of specific genes that play a role in determining left ventricular volume, a key marker of survival in the setting of heart failure (resulting from LV remodeling in the setting of a cardiomyopathy), would be quite valuable. The advent of gene therapy, progenitor cell therapy (stem cells) and emerging molecular genetic approaches to address these genetic anomalies may offer promise.

With the expansion of the UK Biobank database, the expectation is that more genes for cardiac abnormalities will be notified in the future. In fact, UK Biobank announced earlier this month that it will begin sequencing the entire human genome of 450,000 participants, after success of a pilot sequencing trial in 50,000 participants.

Read the rest here:

AI Pinpoints Genes Associated With Heart Failure - Forbes

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment…

Basel, 30 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detect specific fusions with the aim of selecting treatment for people with advanced non-small cell lung cancer (NSCLC), without the need for tissue biopsy. Results from the anaplastic lymphoma kinase (ALK) cohort will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress on Monday 30 September 2019, from 9:15 - 9:30 am CEST (Abstract LBA81 PR), and were also part of the official ESMO press programme.

Obtaining tumour tissue for biomarker testing can be a challenge in many people with cancer and, as a result, some may not receive optimal treatment for their disease, said Sandra Horning, MD, chief medical officer and head of Global Product Development. BFAST is the first trial to show that by using a blood-based next-generation diagnostic, it is possible to identify the ALK mutation in people with non-small cell lung cancer using a blood draw alone, which means that more people could potentially benefit from Alecensa.

Foundation Medicine is pleased to partner with Roche on this study, a first-of-its-kind, pivotal trial that directly demonstrates the clinical utility of using our comprehensive blood-based assay, FoundationOne Liquid, to detect specific fusions and match NSCLC patients with first-line treatment, said Brian Alexander, MD, chief medical officer of Foundation Medicine. Validated and comprehensive liquid biopsy tests are critical to help physicians find the best possible treatment approach for patients with advanced cancer and for whom tissue testing isnt feasible. Identifying ALK fusions can be particularly challenging and these data demonstrate that FoundationOne Liquid can accurately predict which patients can respond to therapy.

The BFAST study used FoundationOne Liquid, Foundation Medicines comprehensive liquid biopsy test, which detects the four main classes of genomic alterations, microsatellite instability (MSI) and select fusions including ALK in circulating tumour DNA (ctDNA) from a blood draw. These data demonstrate that the FoundationOne Liquid assay can help to test and identify a broader population of people with advanced NSCLC who may benefit from Alecensa (alectinib), for whom current diagnostic tests are not suitable, such as for those who cannot provide tissue samples due to insufficient or absent tumour tissue or where tissue diagnostics are not available, and validate the clinical utility of blood-based NGS as an additional method to inform clinical decision-making in ALK-positive NSCLC.

In the study, 87.4% (95% CI: 78.5-93.5) of people with advanced NSCLC who were identified by the FoundationOne Liquid biopsy assay to have ALK fusions had a confirmed response to treatment with Alecensa (overall response rate; ORR) as measured by the investigator per Response Evaluation Criteria in Solid Tumours (RECIST v1.1). This is consistent with the ORR for Alecensa observed in the pivotal Phase III ALEX trial, which identified people using tissue-based testing. When measured using an Independent Review Facility per RECIST v1.1, the confirmed ORR was numerically higher at 92.0% (95% CI: 84.1-96.7). Median progression free-survival (PFS) and duration of response (DoR) were not reached after a median follow-up of 12.6 months. The safety profile of Alecensa was consistent with prior clinical trials and post-marketing experience, with no new safety signals observed.

About the BFAST Study BFAST (Blood First Assay Screening Trial; NCT03178552) is a Phase II/III global, multi-centre, open label, multi-cohort study evaluating the safety and efficacy of targeted therapies or immunotherapies as single agents or in combination in people with unresectable, advanced or metastatic NSCLC determined to harbour oncogenic somatic mutations or be tumour mutational burden (TMB) positive as identified by blood-based NGS ctDNA assays. The Alecensa ALK-positive cohort is the first to readout, with other cohorts due to follow. The primary endpoint for the Alecensa ALK-positive cohort of the BFAST study is confirmed investigator (INV)-assessed ORR. Secondary endpoints include: independent review facility (IRF)-assessed ORR, DoR (INV and IRF), PFS (INV and IRF), overall survival (OS) and safety.

About AlecensaAlecensa (RG7853/AF-802/RO5424802/CH5424802) is a highly selective, CNS active, oral medicine created at Chugai Kamakura Research Laboratories and is being developed for people with NSCLC whose tumours are identified as ALK-positive. ALK-positive NSCLC is often found in younger people who have a light or non-smoking history. It is almost always found in people with a specific type of NSCLC called adenocarcinoma. Alecensa is now approved in 83 countries as an initial (first-line) treatment for ALK-positive, metastatic NSCLC, including in the US, Europe, Japan and China.

About Foundation Medicine Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company, a member of the Roche Group, offers a full suite of comprehensive genomic profiling tests to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.

For more information, please visit http://www.foundationmedicine.com or follow Foundation Medicine on Twitter (@FoundationMedicineATCG).

About Roche in lung cancerLung cancer is a major area of focus and investment for Roche, and we are committed to developing new approaches, medicines and tests that can help people with this deadly disease. Our goal is to provide an effective treatment option for every person diagnosed with lung cancer. We currently have five approved medicines to treat certain kinds of lung cancer and more than ten medicines being developed to target the most common genetic drivers of lung cancer or to boost the immune system to combat the disease.

About RocheRoche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve peoples lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the worlds largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com- Nicolas Dunant (Head)- Patrick Barth- Ulrike Engels-Lange- Daniel Grotzky- Karsten Kleine- Nathalie Meetz- Barbara von Schnurbein

Story continues

See the original post here:

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment...

Skin-Cells-Turned-to-Heart-Cells Help Unravel Genetic Underpinnings of Cardiac Function – UC San Diego Health

By examining heart cells derived from the skin samples of seven family members, researchers at UC San Diego School of Medicine discovered that many genetic variations known to influence heart function do so because they affect the binding of a protein called NKX2-5.

Genome-wide association studies have uncovered more than 500 genetic variants linked to heart function, everything from heart rate to irregular rhythms that can lead to stroke, heart failure or other complications. But since most of these variations fall into areas of the genome that dont encode proteins, exactly how they influence heart function has remained unclear.

By examining heart cells derived from the skin samples of seven family members, researchers at University of California San Diego School of Medicine have now discovered that many of these genetic variations influence heart function because they affect the binding of a protein called NKX2-5.

The study is published September 30, 2019 in Nature Genetics.

NKX2-5 is a transcription factor, meaning it helps turn on and off genes in this case, genes involved in heart development. To do this, NKX2-5 must bind to non-coding regions of the genome. Thats where genetic variation comes in.

NKX2-5 binds to many different places in the genome near heart genes, so it makes sense that variation in the factor itself or the DNA to which it binds would affect that function, said senior author Kelly A. Frazer, PhD, professor of pediatrics and director of the Institute for Genomic Medicine at UC San Diego School of Medicine. As a result, we are finding that multiple heart-related traits can share a common mechanism in this case, differential binding of NKX2-5 due to DNA variants.

The study started with skin samples from seven people from three generations of a single family. The researchers converted the skin cells into induced pluripotent stem cells (iPSCs) as an intermediary. Like all stem cells, iPSCs can both self-renew, making more iPSCs, and differentiate into a specialized cell type. With the right cocktail of molecules and growth factors, the researchers directed iPSCs into becoming heart cells.

These heart cells actually beat in the laboratory dish, and still bear the genetic and molecular features of the individuals from which they were derived.

Frazer and team conducted a genome-wide analysis of these patient-derived heart cells. They determined that NKX2-5 can bind approximately 38,000 sites in the genome. Of those, 1,941 genetic variants affected NKX2-5 binding. The researchers investigated the role of those variants in heart gene function and heart-related traits. One of the genetic variants was associated with the SCN5A gene, which encodes the main channel through which sodium is transported in heart cells.

Since related individuals tend to share similar genetic variants, the team was able to validate their findings by analyzing the same variants in multiple samples.

People typically need a large number of samples to detect the effects of common DNA variants, so we were surprised that we were able to identify with high confidence these effects on NKX2-5 binding at so many sites across the genome with just few people, said first author Paola Benaglio, PhD, a postdoctoral researcher in Frazers lab.

Yet, she said, this finding may just be the tip of the iceberg.

There are probably a lot more genetic variants in the genome involved with NKX2-5 as well as with other important cardiac transcription factors, Frazer said. We identified almost 2,000 in this study, but thats probably only a fraction of what really exists because we were only looking at seven people in a single family and only at one transcription factor. There are probably many more variants in gene regulation sites across the entire population.

Not only does the team plan to further investigate cardiovascular genetics, they also have their sights set on other organ systems.

We are now expanding this same model system to look at many different transcription factors, across different tissue types, such as pancreas and retina epithelia, and scaling it up to include more families, Benaglio said.

Co-authors include: Agnieszka DAntonio-Chronowska, William W. Young Greenwald, Margaret K. R. Donovan, Christopher DeBoever, He Li, Frauke Drees, Sanghamitra Singhal, Hiroko Matsui, Kyle J. Gaulton, Erin N. Smith, Matteo DAntonio, Michael G. Rosenfeld, UC San Diego; Wubin Ma, Feng Yang, Howard Hughes Medical Institute and UC San Diego; Jessica van Setten, University Medical Center Utrecht; and Nona Sotoodehnia, University of Washington.

This research was funded, in part, by the National Institutes of Health (grants HG008118, HL107442, F31HL142151, T32GM008666, P30CA023100, HL116747, HL141989, R01DK114650, DK018477, DK039949), National Science Foundation (grant 1728497), California Institute for Regenerative Medicine (grants GC1R-06673-B, TG2-01154), Swiss National Science Foundation (postdoc mobility fellowships P2LAP3-155105,P300PA-167612), ADA (grant 1-17-JDF-027) and Howard Hughes Medical Institute.

UC San Diegos Studio Ten 300 offers radio and television connections for media interviews with our faculty. For more information, email .(JavaScript must be enabled to view this email address).

See the original post here:

Skin-Cells-Turned-to-Heart-Cells Help Unravel Genetic Underpinnings of Cardiac Function - UC San Diego Health

$1.68 Billion Molecular Diagnostics Point of Care Market – Global Analysis and Forecast, 2019-2029 – Yahoo Finance

DUBLIN, Sept. 30, 2019 /PRNewswire/ -- The "Global Molecular Diagnostics Point of Care Market: Focus on Application, Technology, Type, End User, Country Data (15 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global molecular diagnostic point of care industry analysis projects the market to grow at a significant CAGR of 12.14% during the forecast period, 2019-2029. The molecular diagnostic point of care market generated $1,689.6 million revenue in 2018, in terms of value.

Key Questions Answered in this Report:

The molecular diagnostic point of care market growth has been primarily attributed to the major drivers in this market such as highly increasing global prevalence of infectious diseases and various types of cancer, growing demand for non-invasive diagnostics, increase in adoption of personalized medicines on a global level, and significant external funding for executing research and development exercises. The challenges include an uncertain reimbursement scenario, a lack of high-complexity testing centers, and high capital requirement hampering the global reach.

Scope of the Market Intelligence on Global Molecular Diagnostic Point of Care Market

The molecular diagnostic point of care research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the diagnostic market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, the growth potential of each underlying sub-segment, and company, as well as other vital information with respect to the global molecular diagnostic point of care market.

Market Segmentation

Market Dynamics

Market Drivers

Market Restraint

Market Opportunities

The key manufacturers who have been contributing significantly to the molecular diagnostic point of care market include

For more information about this report visit https://www.researchandmarkets.com/r/wfpdj4

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/1-68-billion-molecular-diagnostics-point-of-care-market---global-analysis-and-forecast-2019-2029--300927707.html

Read more:

$1.68 Billion Molecular Diagnostics Point of Care Market - Global Analysis and Forecast, 2019-2029 - Yahoo Finance

UT Health working to fight children’s cancer with Hyundai Hope on Wheels grant – KENS5.com

SAN ANTONIO UT Health San Antonio is fighting children's cancer in a partnership with Hyundai Hope on Wheels.

To help in the fight against pediatric cancer, Hyundai Hope on Wheels presented two grants totaling $500,000 to UT Health San Antonio for pediatric cancer research Tuesday.

Gregory Aune, M.D., Ph.D., associate professor of pediatric hematology-oncology and an investigator in the Greehey Institute, will receive a $300,000 Hyundai Scholar Hope Award.

The Aune team will test a hypothesis that a particular cell type in the heart is possibly a major contributor to the long-term cardiac toxicity seen in childhood cancer survivors, the press release says.

Amanda Lipsitt, M.D., a third-year fellow in pediatric hematology-oncology, will receive a $200,000 Hyundai Young Investigator Award.

Dr. Lipsitt is studying angiosarcoma, a rare but aggressive form of cancer seen in both children and adults. She is conducting the research in a zebrafish cancer model, the press release says.

The grants will allow both physician-scientists to continue their research into better treatment options, working to eliminate childhood cancer.

Children were able to enjoy the event with finger painting a new Hyundai SUV and taking a laboratory tour.

UT Health San Antonio

UT Health San Antonio

These new research grants provided by Hyundai Hope on Wheels represent a new chapter of hope for children and parents said Peter Houghton, Ph.D., professor of molecular medicine and director of the Greehey Institute.

Link:

UT Health working to fight children's cancer with Hyundai Hope on Wheels grant - KENS5.com

Mergers & Acquisitions in the Global IVD Market, 2019 – Leading Players are Roche, Abbott and Danaher – Yahoo Finance

Dublin, Oct. 01, 2019 (GLOBE NEWSWIRE) -- The "Mergers and Acquisitions in the IVD Market" report has been added to ResearchAndMarkets.com's offering.

In vitro diagnostic (IVD) products continue to see positive sales growth in many categories. New products, changes in global health spending, regulatory changes in major markets and disease trends are among the factors that produce a constantly changing market picture.

In this environment, companies are making strategic acquisitions that simultaneously add a revenue stream and product innovation.

The report looks at these market transactions in Mergers and Acquisitions in the IVD Market, recording more than 220 acquisitions in the diagnostics industry from 2016 to June 2019.

Though some segments of the overall IVD market are still relatively small, they represent the biggest growth areas in the market. The report focuses on acquisitions in these growing segments of great market interest, anticipated to be a big part of the future of IVD, including the following:

The merger and acquisition activities of major players in the market are of course of interest as well, therefore the report provides detailed discussion of activities of leading companies, including:

Detailed listings of company buys are featured in the report:

From 2018 to 2019, the report provides summaries of the market impact of numerous transactions, including:

From 2016 to 2017, the report provides summaries of the market impact of numerous transactions, including:

Key Topics Covered

1: Executive Summary

2: IVD Mergers and Acquisitions

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/jsk83

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Originally posted here:

Mergers & Acquisitions in the Global IVD Market, 2019 - Leading Players are Roche, Abbott and Danaher - Yahoo Finance

Doors Open Day Edinburgh: Each of the 137 venues you can look around this weekend – Edinburgh Live

More than 130 of Edinburgh's most interesting buildings will be opening their doors to the public this weekend.

Doors Open Day will be taking place on Saturday and Sunday (September 28 and 29).

Edinburgh Live reported this week that Leith Police Station, housed in the old court and town hall, is among the venues opening. People will be able to access the striking building on Queen Charlotte Street from 10am to 4pm on Sunday.

A number of venues such as The Playfair at Donaldsons, Barnton Quary ROTOR Bunker and Torness Nuclear Power Station are already fully booked, but there are plenty of other amazing places you can visit across the weekend.

A full list can be found below. To book a spot, or for further information on the events, visit the Doors Open Day website by clicking here.

603 (City of Edinburgh) Squadron, Royal Auxiliary Air Force (28-29 September)

Abbeyhill Baptist Church (28 September)

Abden House, The Confucius Institute (28 September)

Advocates Library (28 September)

Anatomical Museum (28 September)

Appleton Tower: School of Infomatics (28 September)

Arthur Conan Doyle Centre (28-29 September)

Assembly Rooms (28 September)

Astley Ainslie Hospital (28-29 September)

Astoria Centre (29 September)

Augustine United Church (28-29 September)

Barnton Quarry ROTOR Bunker (28-29 September)

Bayes Centre (29 September)

Bellfield (29 September)

Bridgend Farmhouse (29 September)

Buccleuch & Greyfriars Free Church of Scotland (28 September)

Burns Monument (28-29 September)

Canongate Kirk & Kirkyard (28-29 September)

Castle Mills (Edinburgh Printmakers) (28-29 September)

Chalmers Church (28 September)

Chapel of St Albert the Great (28-29 September)

Chapel of St John (28-29 September)

Charlotte Chapel (28 September)

Church of the Sacred Heart (28 September)

Cockburn Association (28-29 September)

Collective, City Observatory, Calton Hill (28-29 September)

Corstorphine Hill Tower (28-29 September)

Cottage, West Princes Street Gardens (28-29 September)

Craigsbank Parish Church (28-29 September)

Custom House Leith (28 September)

Dean Gardens (29 September)

Dovecot Studios (28 September)

Dower House (28 September)

Drumsheugh Baths Club (28 September)

Edinburgh Baha'i Centre (28 September)

Edinburgh Law School, Old College (28 September)

Edinburgh Sculpture Workshop (28 September)

Edinburgh Sheriff and Justice of the Peace Court (28 September)

Festival Theatre Edinburgh (28 September

Fountainbridge Library (28 September)

Georgian Antiques (29 September)

Gogar Cabinet Works (28-29 September)

Granton Castle Walled Garden (28 September)

Greyfriars Kirk (28-29 September)

Grove Community Garden (28 September)Harlaw House Visitor Centre (28 September)

Harmeny School (29 September)

Herbarium & Library Building - Royal Botanic Gardens (28 September)

Inch House Community Centre (29 September)

Informatics Forum (29 September)

Institut Francais D'Ecosse (28-29 September)

Institution of Civil Engineers (ICE) Scotland Museum (28 September)

James Clerk Maxwell Foundation (28 September)

JM Architects (28 September)

John Knox House (28 September)

Kings Theatre Edinburgh (29 September)

King's Buildings (28 September)

Leith Theatre (29 September)

Leith Town Hall & Sheriff Court (29 September)

Lothian Buses (28 September)

Magdalen Chapel (28 September)

Mayfield Salisbury Parish Church of Scotland (28 September)

Meadows Croquet Club (28 September)

Morningside Cemetary (28 September)

MRC Institute of Genetics and Molecular Medicine (28 September)

National Galleries of Scotland - Granton Art Centre (28 September)

National Library of Scotland (28 September)

National Library of Scotland (Causewayside) (28 September)

National Museums Collection Centre - SOLD OUT (28 September)

New Register House (28 September)

Newington Cemetery (29 September)

North Edinburgh Arts Garden (28 September)

Northern Lighthouse Board (28-29 September)

Oakvale Funeral Home (28-29 September)

Old College, University of Edinburgh (28-29 September)

Oriam - Scotland's Sports Performance Centre (28 September)

Out of the Blue Drill Hall (29 September)

Panmure House (29 September)

Parish Church of St Cuthbert (28 September)

Playfair at Donaldsons (29 September)

Police Box (28 September)

Portobello Baptist Church (28 September)

Priory Church of St Mary of Mount Carmel (28-29 September)

Queen Street Gardens Central and East Districts (28 September)

Queen's Nursing Institute Scotland (28 September)

Queensferry Parish Church (28 September)

Ramp House (29 September)

Ratho Byres Forge (28-29 September)

Redhall Walled Garden (SAMH) (28 September)

Regent, Royal and Calton Terrace Gardens (29 September)

Riddle's Court (28-29 September)

Royal Observatory Edinburgh (28-29 September)

Scottish Arts Club (28-29 September)

Scottish Free French House, Official Residence of the Consul General of France (28-29 September)

Scottish Mineral and Lapidary Club (28-29 September)

Seafield Treatment Centre - Veolia (28-29 September)

Original post:

Doors Open Day Edinburgh: Each of the 137 venues you can look around this weekend - Edinburgh Live

Drive high CAGR by Global Bioinformatics Market Along with Top Key Players like Life Technologies, Illumina, Inc., Agilent Technologies and Active…

Global Bioinformatics Market Industry Analysis:Bioinformatics is the combination of biology and information technology. It is used widely in the management of biological information in the field of medical research and development of drugs. It uses computer software tools for database creation, data management, data warehousing, data mining and communication networking. Bioinformatics deals with the recording, annotation, storage, analysis and retrieval of nucleic acid sequence, protein sequence and structural information. It has several applications in the fields of medicine and biology including molecular medicines, preventive medicines, gene therapy, drug developments, biotechnology and forensic analysis of microbes. It is also used in the study of genetics and genomes.

The Bioinformatics market research study relies upon a combination of primary as well as secondary research. It throws light on the key factors concerned with generating and limiting Bioinformatics Market growth. In addition, the current mergers and acquisition by key players in the market have been described at length. Additionally, the historical information and growth in the CAGR have been given in the research report. The latest trends, product portfolio, demographics, geographical segmentation, and regulatory framework of the Bioinformatics market have also been included in the study.

Sample of this Report: https://www.acquiremarketresearch.com/sample-request/201553/

The Global Bioinformatics Market Can Be Segmented As

Top key Players: Life Technologies, Illumina, Inc., Agilent Technologies and Active Motif, Inc., Bio-Rad LaboratoriesQIAGEN, Knome, Inc., GE Healthcare, Quest Diagnostics ,

ProductKnowledge Management Tools, Data Analysis Platforms ,

Product Application Genomics, Chemoinformatics and Drug Design, Proteomics, Transcriptomics, Metabolomics, Others ,

The research report on the Global Bioinformatics Market is a comprehensive study of the current scenario of the market, covering the key market dynamics. The report also provides a logical evaluation of the key challenges faced by the leading pioneers operating in the market, which helps the participants in understanding the difficulties they may face in future while functioning in the global market over the forecast period.

To get this report at beneficial rates: https://www.acquiremarketresearch.com/discount-request/201553/

The Bioinformatics industry research report studies the production, supply, sales, and the current status of the market in a profound manner. Furthermore, the report studies the production shares and market product sales, as well as the capacity, production capacity, sales, and revenue generation. Several other factors such as import/export status, demand, supply, gross margin, and industry chain structure have also been studied in the Global Bioinformatics Market report.

This study gives data on patterns and improvements, and spotlights on Markets and materials, limits and on the changing structure of the Bioinformatics Industry. The key motivation behind the report is to give a proper and key examination of this industry.

Get More Details @https://www.acquiremarketresearch.com/industry-reports/bioinformatics-market/201553/

Reasons to buy this report:

Understand the current and future of the Keyword Market in both developed and emerging markets.

The report assists in realigning the business strategies by highlighting the Keyword business priorities.

The report throws light on the segment expected to dominate the Keyword industry and market.

Forecasts the regions expected to witness the fastest growth.

In the end, Bioinformatics Market Report delivers a conclusion which includes Breakdown and Data Triangulation, Consumer Needs/Customer Preference Change, Research Findings, Market Size Estimation, Data Source. These factors will increase the business overall.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, Europe.

See the rest here:

Drive high CAGR by Global Bioinformatics Market Along with Top Key Players like Life Technologies, Illumina, Inc., Agilent Technologies and Active...

Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers | Small Molecules | News…

DetailsCategory: Small MoleculesPublished on Tuesday, 01 October 2019 13:24Hits: 111

- LIBRETTO-001 is the largest trial ever reported in RET-altered cancer patients

- 56 percent objective response rate (ORR) in the registration dataset (n=55) of RET-mutant medullary thyroid cancer (MTC) patients who had previously received cabozantinib and/or vandetanib

- 59 percent ORR in cabozantinib/vandetanib-nave RET-mutant MTC patients

- 62 percent ORR in heavily pretreated RET fusion-positive thyroid cancer patients

- Sustained durability, measured by both Duration of Response and Progression-Free Survival

- Well-tolerated safety profile; low rate of discontinuation (1.7%) for treatment-related adverse events

- New Drug Application to be submitted by year-end

INDIANAPOLIS, IN, USA I September 29, 2019 I Eli Lilly and Company (NYSE: LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib1 monotherapy, also known as LOXO-292, for the treatment of RET-altered thyroid cancers. RET-altered thyroid cancers are comprised of two different populations, RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancers. In the RET-mutant MTC registration dataset consisting of the first 55 enrolled patients with prior cabozantinib and/or vandetanib2, selpercatinib treatment resulted in a 56 percent objective response rate (ORR) (95% CI: 42-70%). This population was heavily pretreated (53 percent previously treated with 2 prior multikinase inhibitors), and ORR was similar regardless of prior multikinase inhibitor therapy. As of the data cut-off date of June 17, 2019, median duration of response (DOR) was not reached (95% CI: 11.1-NE) and median progression-free survival (PFS) was not reached (95% CI: 11.3-NE). Selpercatinib therapy also resulted in robust biochemical response rates (BRR) for serum tumor markers calcitonin (91% BRR) and carcinoembryonic antigen (64% BRR). In a safety analysis of all 531 patients enrolled to LIBRETTO-001, selpercatinib was well-tolerated, with only nine patients (1.7%) discontinuing therapy due to treatment-related adverse events. The most commonly observed adverse events, regardless of attribution, were dry mouth, diarrhea, hypertension, increased liver enzymes, fatigue, constipation, and headache. These results were presented today at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain, in session LBA93, Registrational Results of LOXO-292 in Patients with RET-Altered Thyroid Cancers, presented by Lori J. Wirth, M.D., medical director of head and neck cancers, Massachusetts General Hospital Cancer Center in Boston, Mass. Selpercatinib has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA).

"Current therapeutic options are often challenging for patients with first-line RET-altered thyroid cancers and are limited for patients who relapse. The data for selpercatinib show demonstrative efficacy and safety in both the first-line and relapsed settings. Patients with thyroid cancer have long sought targeted therapy tailored to the molecular nature of their disease, and we are hopeful that selpercatinib may be used as the standard of care in the future," said Wirth, who is lead investigator on the trial.

Selpercatinib Data in Cabozantinib/Vandetanib-Nave RET-Mutant MTC patientsInvestigators also presented the results of selpercatinib in RET-mutant MTC patients who have received neither cabozantinib nor vandetanib. In this analysis of 76 patients, selpercatinib treatment resulted in a 59 percent ORR (95% CI: 47-70%). Median DOR and PFS were not reached in this treatment-nave population, as the vast majority of patients remain in response or progression-free.

Selpercatinib Data in Heavily Pretreated RET Fusion-Positive Thyroid Cancer PatientsInvestigators also presented the results of selpercatinib in heavily pretreated RET fusion-positive thyroid cancer patients. In this analysis of 26 patients, selpercatinib treatment resulted in a 62 percent ORR (95% CI: 41-80%). Median DOR and PFS were not reached in this population, as the vast majority of patients remain in response or progression-free.

"We're pleased that selpercatinib may offer a meaningful advance for patients with RET-altered thyroid cancers," said Anne White, president of Lilly Oncology. "These patients have been a focus of the selpercatinib program from its beginning, as RET has been a known oncogene in these diseases for decades. With these data, selpercatinib has delivered on our vision, with unprecedented clinical outcomes in both first-line and relapsed patients, particularly in light of the difficult options for these patients."

Trial BackgroundThe LIBRETTO-001 Phase 1/2 trial is the largest clinical trial of patients with RET-altered cancers treated with a RET inhibitor. The trial includes a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2). The Phase 2 portion of the trial had a primary endpoint of objective response rate (ORR) and secondary endpoints of DOR, PFS and safety. The primary analysis set for MTC regulatory submissions, as defined with the FDA, consists of the first 55 enrolled patients with RET-mutant medullary thyroid cancer who have experienced prior cabozantinib and/or vandetanib. All data presented at ESMO were as of a data cut-off date of June 17, 2019, and all efficacy measures utilized investigator assessments.

About Selpercatinib (LOXO-292)Selpercatinib, also known as LOXO-292, is a highly selective and potent, oral investigational new medicine in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase. RET fusions and mutations occur across multiple tumor types with varying frequency. Selpercatinibwas designed to inhibit native RET signaling as well as anticipated acquired resistance mechanisms.

Selpercatinib has received breakthrough designation for the treatment of patients with:

About RET-Altered CancersGenomic alterations in RET kinase, which include fusions and activating point mutations, lead to overactive RET signaling and uncontrolled cell growth. RET fusions have been identified in approximately 2 percent of non-small cell lung cancer, 10-20 percent of papillary and other thyroid cancers and a subset of other cancers. Activating RETpoint mutations account for approximately 60 percent of MTC. RET fusion cancers and RET-mutant MTC are primarily dependent on this single activated kinase for their proliferation and survival. This dependency, often referred to as "oncogene addiction," renders such tumors highly susceptible to small molecule inhibitors targeting RET.

About Lilly OncologyFor more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly's commitment to people with cancer, please visit http://www.LillyOncology.com.

About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. P-LLY

1PINN, pending USAN approval2The multikinase inhibitors, cabozantinib and vandetanib, are both FDA-approved for the treatment of progressive and metastatic medullary thyroid cancer regardless of RET mutation status.

SOURCE: Eli Lilly

See the rest here:

Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers | Small Molecules | News...

The Innovation of Women in Medicine: A Kean Analysis – The Tower

By Tasha Dowbachuk | Published by September 19th, 2019

On Sept. 11, the American Medical Womens Association (AMWA) held an interest meeting in the Miron Student Center at 11:30 a.m., welcoming students in discovering the mission and values within their organization at Kean University.

The informational event of the organization presented their commitment to promoting excellence in medical communication while providing educational resources in support of women empowerment in medicine.

According to its website, the organization was founded by Dr. Bertha VanHoosen in 1915 in Chicago. The first international organization of medical women was founded in 1919, with the intention of representing women in medicine worldwide.

Informative bulletin board of the American Medical Womens Association.Photo by Tasha Dowbachuk

Today, AMWA provides networking opportunities and in-depth discussions about the future of medicine to anyone who is interested or involved in the medical field. The event was hosted by Vice President Julia CurtisDye, who is majoring in Cell and Molecular Biology, along with the members of the association.

Through the free membership of the campus chapter, members are given the opportunity to participate in national conferences, mentorships, and scholarship benefits by joining the national branch of AMWA through a $35 payment.

I think to give some of our members their first glance of the medical field and helping them get closer to their goals through the memberships, as women in a male-dominated field, is one of our greatest achievements, said CurtisDye. Our job is to connect people to our Kean branch membership for free or connect to the national branch membership under a $35 fee to attend the national conferences, mentorships which cover for your entire undergraduate journey.

Marina Georges, a senior psychology major with a minor in biology, is serving her first year as the President of AMWA this semester. After becoming a member of the chapter, the unification of a sisterhood bond within the organization inspired her to expand and motivate members into pursuing the medical field.

When we bring great minds together, in science, we can bring better public health and hopefully finding cures through the unity within this organization, said Georges. Having that common ground, like a group of strong sisters who support each other, creates something so beautiful for the future of medicine.

The president of AMWA, Marina Georges (left) with Vice president, Julia CurtisDye (right).Photo by Tasha Dowbachuk

The association also provides guidance for admissions processing and preparing for the Medical College Admission Test (MCAT exam).

According to the Princeton Review, the MCAT is a 7.5 hour exam that consists of four sections: Biological and Biochemical Foundations of Living Systems; Chemical and Physical Foundations of Biological Systems; Psychological, Social, and Biological Foundations of Behavior; and Critical Analysis and Reasoning Skills.

We brought in Kean alumni, who shared their experiences in the field and how AMWA helped them in becoming a physician assistant. said Georges.

The academic and social aspects of the association are not restrictive to male students who are interested in joining.

Related

Go here to see the original:

The Innovation of Women in Medicine: A Kean Analysis - The Tower

CRISPR fix in mice may lead to muscular dystrophy therapy – Futurity: Research News

Share this Article

You are free to share this article under the Attribution 4.0 International license.

The CRISPR gene editing technique may provide the means for lifelong correction of the genetic mutation responsible for Duchenne muscular dystrophy, a new study with mice shows.

Duchenne muscular dystrophy (DMD), a rare but devastating genetic disorder, causes muscle loss and physical impairment. Children with DMD have a gene mutation that interrupts the production of a protein known as dystrophin. Without it, muscle cells weaken and eventually die. Many children lose the ability to walk, and muscles essential for breathing and heart function ultimately stop working.

Research has shown that CRISPR can be used to edit out the mutation that causes the early death of muscle cells in an animal model, says Dongsheng Duan, professor in medical research in the molecular microbiology and immunology department at the University of Missouri School of Medicine and senior author of the paper in Molecular Therapy.

However, there is a major concern of relapse because these gene-edited muscle cells wear out over time. If we can correct the mutation in muscle stem cells, then cells regenerated from the edited stem cells will no longer carry the mutation. A one-time treatment of the muscle stem cells with CRISPR could result in continuous dystrophin expression in regenerated muscle cells.

For the study, researchers explored whether they could efficiently edit muscle stem cells from mice. They first delivered the gene editing tools to normal mouse muscle through AAV9, a virus that the US Food and Drug Administration recently approved to treat spinal muscular atrophy.

We transplanted AAV9 treated muscle into an immune-deficient mouse, says lead author Michael Nance, a MD-PhD program student in Duans lab. The transplanted muscle died first then regenerated from its stem cells. If the stem cells were successfully edited, the regenerated muscle cells should also carry the edited gene.

The researchers reasoning was correctthey found abundant edited cells in the regenerated muscle. They then tested if they could use CRISPR to edit muscle stem cells in a mouse model of DMD. Similar to what they found in normal muscle, the stem cells in the diseased muscle were also edited. Cells regenerated from these edited cells successfully produced dystrophin.

This finding suggests that CRISPR gene editing may provide a method for lifelong correction of the genetic mutation in DMD and potentially other muscle diseases, Duan says.

Our research shows that CRISPR can be used to effectively edit the stem cells responsible for muscle regeneration. The ability to treat the stem cells that are responsible for maintaining muscle growth may pave the way for a one-time treatment that can provide a source of gene-edited cells throughout a patients life.

With more study, the researchers hope this stem cell-targeted CRISPR approach may one day lead to long-lasting therapies for children with DMD.

Additional coauthors are from the University of Missouri, the National Center for Advancing Translational Sciences, Johns Hopkins School of Medicine, and Duke University. The National Institutes of Health, the Department of Defense, the Jackson Freel DMD Research Fund, Hope for Javier, and the Intramural Research Program of the National Center for Advancing Translational Sciences funded the work.

Source: University of Missouri

The rest is here:

CRISPR fix in mice may lead to muscular dystrophy therapy - Futurity: Research News

7 Days in Science September 13, 2019 – Technology Networks

Breakthrough in Preventing Chemotherapy-induced Hair Loss

Scientists have uncovered a novel method that could potentially prevent chemotherapy-induced hair loss, with the use of an ex vivo organ culture model.

Published in:EMBO Molecular Medicine

Read full story

Compound Created to Help Reconstruct Myelin in Multiple Sclerosis

Researchers have created a compound, that when tested in mice, was able to promote the reconstruction of the myelin sheath surrounding neuronal axons.

Published in:Glia

Read full story

Analytical Science Puts Historical Claims to the Test

The latest analytical techniques available to scientists are being used to confirm the validity of historical artifacts and claims in some cases, and suggest a need for reconsideration in others.

Published in:Eur. Phys. J. PlusRead full story

"Pathobiome" Gives New Angle on Disease

Scientists have presented a novel concept describing the complex microbial interactions that lead to disease in plants, animals and humans. The "pathobiome" concept could be applied to enhance production of many species, such as shrimp, a major aquaculture product globally.

Published in:Trends in Ecology and EvolutionRead full story

A Toast To the Genetic Diversity of Grapes

A research team has deciphered the genome of the Chardonnay grape. By doing so, they have uncovered something fascinating: grapes inherit different numbers of genes from their mothers and fathers.

Published in: Nature PlantsRead full story

When a stroke occurs, the blood supply to parts of the brain is either interrupted, reduced or stopped, depriving the brain of the oxygen and essential nutrients it requires to function. Consequently, brain cells begin to die. In a new study using a mouse model of ischemic stroke, researchers have successfully converted glial cells into new neurons. This may form the basis of a novel gene therapy for stroke treatment.

Read more here

Transplant recipients immune systems recognize donor organs as "foreign" and can attack them in a bid to eliminate them from the body. Immunosuppressive drugs can help to minimizethe magnitude of rejection but are not always successful long-term and their use comes with adverse effects of their own. In this article we take a look at the potentialof 3D bioprinting technologies as a way to eliminate the chancesof rejection, by generating organs in the lab from patients' own cells.

Read more here

TSE Explores Microplastics What are Microplastics?

Creating Protein Patterns

Credit: Nancy Hernandez, William Hansen and Slava Manichev

Read more here:

7 Days in Science September 13, 2019 - Technology Networks

Washington People: Gwen Randolph – Washington University School of Medicine in St. Louis

Visit the News Hub

Immunologist shows that the journey is as important as the destination

Gwendalyn Randolph, PhD, talks in her lab with postdoctoral researcher Rafael Czepielewski, PhD. An immunologist by training, Randolph studies immune cells and how they travel around the body in conditions as diverse as inflammatory bowel and cardiovascular disease.

A few years ago, as immunologist Gwendalyn Randolph, PhD, and postdoctoral researcher Li-Hao Paul Huang, PhD, hashed out a research plan, the two realized they had a problem. They were studying inflammatory bowel disease (IBD), and they needed human participants for a study looking at how fat travels from the intestine to the blood. But they had never done a human study that required more of participants than donating a small amount of blood. Worse, they didnt have a local clinical collaborator since Randolph, the Emil R. Unanue Distinguished Professor of Immunology at Washington University School of Medicine in St. Louis, had just recently arrived in St. Louis from Icahn School of Medicine at Mount Sinai in New York City.

Randolph and Huang started designing a study to be conducted at Mount Sinai, where Randolph still had many collaborators. But to do so, they needed to figure out how the fats would be delivered to participants and brought back to St. Louis for analysis.

First, we were concerned with formulating a fat-rich meal that would be palatable and could be made reproducibly by our colleagues in New York, Huang said. We went to Gwens house, and we prepared a milkshake with ice cream and whole milk and the other ingredients needed for the study including fat molecules that could be traced in the laboratory and we drank it.

The taste test was successful, but luckily, it turned out to be unnecessary. Not long after, Washington University gastroenterologist Matthew Ciorba, MD, approached Randolph and suggested a collaboration. And soon, other School of Medicine faculty members gastroenterologist Parakkal Deepak, MBBS, and nutrition experts Bettina Mittendorfer, PhD, Bruce Patterson, PhD, and W. Todd Cade, PhD signed on as well. Together, they redesigned the study to leverage Washington Universitys prowess in translational medicine. Randolph was only too happy to leave milkshake formulation to the true experts.

The study is nearing completion. It represents a remarkable shift in focus for Randolph, who began her career studying how immune cells travel around the body.

Shes just a fantastic scientist, said Paul Allen, PhD, the Robert L. Kroc Professor of Pathology and Immunology and a collaborator of Randolphs. She used to work on innate immune cells, but then she blossomed out into cardiovascular disease, lipid metabolism, the gut. Its just amazing how she finds these connections between different fields.

Randolph has a long track record of breaking down scientific silos. An immunologist by training, she made a name for herself in cardiovascular and inflammation research by asking questions no one else had thought to ask.

For her, its like solving mysteries, said Melody Swartz, PhD, a professor of molecular engineering at the University of Chicago and a longtime collaborator of Randolphs. She just really cares about science. She is not interested in awards or being the first to publish; she really and truly only cares about figuring out whats going on.

Gwen Randolph, PhD (center), laughs with staff scientist Shashi Bala Kumar (left) and postdoctoral researcher Rafael Czepielewski, PhD.

An accidental scientist

If the stars had aligned just a bit differently, Randolph, who is also a professor of medicine, might never have become a scientist at all. Raised on a maize and cotton farm outside the small town of Hart in the Texas Panhandle, she grew up hoeing weeds and helping with the harvest.

As a teenager, she exhibited a talent for sewing and design that won her awards and trips to New York and Los Angeles. But when she started talking about moving east to study textiles after high school, her parents both descended from generations of Southern farmers hesitated. So instead, she accepted a basketball scholarship to Wayland Baptist University in nearby Plainview, Texas, and enrolled in pre-med courses.

I thought I was going to be a doctor, but in the spring of my first year, I fell in love with histology, Randolph recalled, referring to the microscopic structure of tissues. I can remember sitting in a laundromat, doing my laundry, reading this book on how white blood cells leave the bloodstream and go into tissues, and I was just fascinated. It was very historical, and I remember wondering if anyone was still studying that stuff.

Not many people were, it turned out. Immunologists love to study the immune systems lymph nodes, where cells that have encountered infectious organisms or signs of injury go to alert other cells about the danger in their midst. But immunologists dont tend to spare much thought for the journey immune cells take on their way to the lymph nodes. Once she had the scientific training, Randolph returned to the question that had first piqued her interest what happens en route to the lymph nodes and began to investigate. She was fascinated to learn that lymphatic vessels that connect lymph nodes are far from an inert network of tubing. The vessels dilate or constrict to slow or speed the rate of travel. She showed that the constricting lymphatic vessels leak many signaling molecules into the surrounding tissue, and these signals are captured by other immune cells that, in turn, respond to help regulate immunity. All these functions add up to a pivotal role for the lymphatics in shaping the immune response.

Everyone was throwing away the fatty tissue that is outside of lymph nodes because its boring, Randolph said. But fat is what links all the organs to the various lymph nodes that collect drainage from our tissues, and it turns out all kinds of things are happening in the fat.

That brief textbook passage on histology eventually led Randolph to break down the wall separating lymphatic biology and immunology, and show that how cells and molecules get places is just as important as where theyre going.

Blazing a trail in New York

After two years at Wayland Baptist, Randolph moved to Pennsylvania, where she completed her undergrad studies at Temple University. From there, she moved to the State University of New York, Stony Brook, for graduate school, and then to Rockefeller University and Weill Cornell Medicine for postdoctoral studies.

In New York, while a postdoc at Rockefeller and Weill Cornell, Randolph worked closely with Ralph Steinman, MD, who went on to win the Nobel Prize in Physiology or Medicine in 2011 for his discovery of the dendritic cell the cell type that orchestrates and conducts the immune response.

In collaboration with Steinman, Randolph published a paper in Science in 1998 showing that dendritic cells mature from a different immune cell type and that dendritic cells are compelled to migrate to lymph nodes. As part of the study, Randolph grew immune cells in collagen matrices below a layer of cells that line the inner surface of blood vessels. The immune cells passed through the blood vessel cells and migrated upward, toward the rim of the wells. They had presumably climbed through the blood vessel-cell layer in search of lymphatic vessels that would, in a living animal, take them to the lymph nodes. The strong propensity of dendritic cells to migrate to lymph nodes, even when lymph nodes were not part of the experimental setup, fueled her research on lymphatic vessels.

Randolph met her future husband, Hermann Kyrychenko, at an art gallery while on vacation in Prague, and within a year, he moved to New York to be with her. Today, they have two children: Anton, 14, and Athena, 11.

Gwen Randolph relaxes with her husband, Hermann Kyrychenko; son, Anton; daughter, Athena; and the family dog, Lily.

A Ukrainian national by birth who has worked as a translator, a paramedic, an art gallery docent and a martial arts instructor, Kyrychenko did much of the child-raising while Randolph established a lab at Mount Sinai and started exploring the relationship between the lymphatics and other systems of the body, notably the cardiovascular system.

Immune cells known as macrophages help keep blood flowing smoothly by eating up the cholesterol that sometimes collects inside blood vessels. Randolph hypothesized that, after consuming cholesterol, macrophages migrate from the bloodstream through the lymphatics to dispose of the cholesterol, and that problems with the lymphatics could cause the sticky substance to build up, raising the risk of heart attack. This hypothesis proved untrue, but the process of investigating it unveiled other key observations on macrophages, including how much macrophages vary from organ to organ.

What I really like about Gwen is that she goes where the data take her, said Robert Gropler, MD, a professor of radiology who works with Randolph to develop new positron emission tomography (PET) imaging probes designed to detect signs of inflammation and immunity. She maintains an open mind, and because of that, shes a highly innovative scientist. Her real strength is the breadth and depth of her knowledge. She knows not only her own field but other fields well enough to see how they could benefit from collaboration. Shes just a really incredible resource for the university.

Along with her willingness to pursue novel scientific ideas, Randolph has earned a reputation for being willing to stand up for what she believes, especially on issues affecting women and people who arent in positions of power. At Mount Sinai, she helped establish a lactation room after several postdocs in her lab and neighboring labs gave birth, and she realized they had nowhere clean and private to pump milk. She once challenged the dean of the School of Medicine at Mount Sinai to a basketball game both loved the sport to settle a dispute over the schools policy of taking a cut of postdocs career award funding to beef up indirect cost recovery from those awards. The game never happened, but a compromise for the source of the indirect costs was reached, with the departments rather than the investigators covering the required amount. At Washington University, she has continued to voice concerns that touch on social justice.

She will never allow something wrong to happen in front of her eyes without fighting against it, said Miriam Merad, MD, PhD, an immunologist at Mount Sinai who worked with Randolph for many years. It has sometimes been to her detriment to be so vocal. But Gwen will always fight for the cause she believes in.

Finding a scientific home in the Midwest

In 2011, when word began to spread at Mount Sinai that her department was closing, Randolph took a job at Washington University. She resettled her family in Clayton, partly because it was close enough for her to bike across Forest Park to work every day.

I might be the only one from the Panhandle of Texas who ever existed who doesnt like cars, Randolph said. We have a car, but I refuse to drive to work.

In Clayton, she cultivates a varied and thriving vegetable and herb garden. When Huang dropped by her home one afternoon to pick up some reagents he needed in the lab, Randolph treated him to homemade vegetable pizza, marinated cucumbers, basil ice cream That was a bit weird, Huang said and cake with blackberry sauce. Most of the produce for the meal had been harvested from her own backyard.

Just before Randolph moved to St. Louis, a chance conversation at Mount Sinai changed the course of her research.

My graduate student was presenting her research on fat and lymphatics, and one of my colleagues turned to me and joked, There is only one person who is interested in fat and lymphatics other than you: Jean-Frederic Colombel, Randolph said. So I called him up.

Colombel turned out to be a gastroenterologist who specializes in Crohns disease. He introduced Randolph to the peculiar creeping fat that grows up around the intestine near sites of damage in IBD. The fat is associated with strictures in the intestine that can cause bowel obstruction and necessitate emergency surgery. Colombel thought the fat was not just a curiosity but was contributing to the disease. Intrigued, Randolph began collaborating with Colombel to investigate the role of fat and lymphatics in IBD.

I make decisions, and I move forward, and I dont spend a lot of time thinking, Does it make sense to take on this risk? Randolph said. Some doors close, and I open other doors and move forward.

In 2015, she received a prestigious Pioneer Award from the National Institutes of Health (NIH) to study how gut inflammation affects the lymphatic vessels near the intestine. She suspects that inflammatory cells release proteins that cause the vessels to constrict, impeding the flow of immune cells and proteins and contributing to a dysfunctional inflammatory response.

She also suspects that the fat itself is part of the problem. Some of the fat leaves the intestines and travels through the lymphatics to the bloodstream, converting into fatty acids along the way. Some fatty acids are highly inflammatory, so roaming fat could be contributing to the destructive inflammation of the disease.

Although the work is still in its early stages, it could transform our understanding of how IBD develops and progresses, and lead to novel strategies for treating the disease.

She is a completely independent thinker, an innovator, Merad said. Nothing surprises me coming from Gwen. If you told me she has become an astronaut, I would not be surprised. She dares and never looks back.

Immune cells cause cholesterol to be trapped in blood vessels

Read more here:

Washington People: Gwen Randolph - Washington University School of Medicine in St. Louis

In human cells and mice, a cure for the common cold, Stanford-UCSF study reports – Stanford Medical Center Report

Temporarily disabling a single protein inside our cells might beable to protect us from the common cold and other viral diseases, according to a study led by researchers at Stanford University and University of California-San Francisco.

The findings were made in human cell cultures and in mice.

Our grandmas have always been asking us, If youre so smart, why havent you come up with a cure for the commoncold?said Jan Carette, PhD, associate professor of microbiology and immunology. Now we have a new way to do that.

The approach of targeting proteins in our own cells also worked to stop viruses associated with asthma, encephalitis and polio.

Colds, or noninfluenza-related upper respiratory infections, are for the most part a weeklong nuisance. Theyre also the worlds most common infectious illness, costing the United States economy an estimated $40 billion a year. At least half of all colds are the result of rhinovirus infections. There are roughly 160 known types of rhinovirus, which helps to explain why getting a cold doesnt stop you from getting another one a month later. Making matters worse, rhinoviruses are highly mutation-prone and, as a result, quick to develop drug resistance, as well as to evade the immune surveillance brought about by previous exposure or a vaccine.

In a study published online Sept. 16 inNature Microbiology, Carette and his associates found a way to stop a broad range of enteroviruses, including rhinoviruses, from replicating inside human cells in culture, as well as in mice. They accomplished this feat by disabling aprotein in mammalian cells thatall enteroviruses appear to need in order to replicate.

Carette shares senior authorship with Or Gozani, MD, PhD, professor of biology at Stanford and the Dr. Morris Herzstein Professor of Biology; Raul Andino, PhD, professor of microbiology and immunology at UCSF; and Nevan Krogan, PhD, professor of cellular and molecular pharmacology at UCSF. The lead authors are former Stanford graduate student Jonathan Diep, PhD, and Stanford postdoctoral scholars Yaw Shin Ooi, PhD, and Alex Wilkinson, PhD.

One of the most well-known and feared enteroviruses is poliovirus. Until the advent of an effective vaccine in the 1950s, the virus spelled paralysis and death for many thousands of children each year in the United States alone. Since 2014, another type of enterovirus, EV-D68, has been implicated inpuzzling biennialbursts of a poliolike disease, acute flaccid myelitis, in the United States and Europe. Other enteroviruses can cause encephalitis and myocarditis inflammation of the brain and the heart, respectively.

Like all viruses, enteroviruses travel lightly. To replicate, they take advantage of proteins in the cells they infect.

To see what proteins in human cells are crucial to enteroviral fecundity, the investigators used a genomewide screen developed in Carettes lab. They generated a cultured line of human cells that enteroviruses could infect. The researchers then used gene editing to randomly disable a single gene in each of the cells. The resulting culture contained, in the aggregate, cells lacking one or another of every gene in our genome.

The scientists infected the culture with RV-C15, a rhinovirus known to exacerbate asthma in children, and then with EV-C68, implicated in acute flaccid myelitis. In each case, some cells managed to survive infection and spawn colonies. The scientists were able to determine which gene in each surviving colony had been knocked out of commission. While both RV-C15 and EV-D68 are both enteroviruses, theyre taxonomically distinct and require different host-cell proteins to execute their replication strategies. So, most of the human genes encoding the proteins each viral type needed to thrive were different, too. But there were only a handful of individual genes whose absence stifled both types ability to get inside cells, replicate, bust out of their cellular hotel rooms and invade new cells. One of these genes in particular stood out. This gene encodes an enzyme called SETD3. It was clearly essential to viral success, but not much was known about it, Carette said.

The scientists generated a culture of human cells lacking SETD3 and tried infecting them with several different kinds of enterovirus EV-D68, poliovirus, three different types of rhinovirus and two varieties of coxsackievirus, which can cause myocarditis. None of these viruses could replicate in the SETD3-deficient cells, although all proved capable of pillaging cells whose SETD3-producing capability was restored.

The researchers observed a 1,000-fold reduction in a measure of viral replication inside human cells lacking SETD3, compared with controls. Knocking out SETD3 function in human bronchial epithelial cells infected with various rhinoviruses or with EV-D68 cut replication about 100-fold.

Mice bioengineered to completely lack SETD3 grew to apparently healthy adulthood and were fertile, yet they were impervious to infection by two distinct enteroviruses that can cause paralytic and fatal encephalitis, even when these viruses were injected directly into the mices brains soon after they were newly born.

In contrast to normal mice, the SETD3-deficient mice were completely unaffected by the virus, Carette said. It was the virus that was dead in the water, not themouse.

Enteroviruses,the scientists learned, have no use for the section of SETD3 that cells employ for routine enzymatic activity. Instead, enteroviruses cart around a protein whose interaction with a different part of the SETD3 molecule, in some as yet unknown way, is necessary for their replication.

This gives us hope that we can develop a drug with broad antiviral activity against not only the common cold but maybe all enteroviruses, without even disturbing SETD3s regular function in our cells, Carette said.

Carette and Gozani are members of Stanford Bio-X and the Stanford Maternal & Child Health Research Institute, as well as faculty fellows of Stanford ChEM-H. Gozani is a member of the Stanford Cancer Institute.

Other Stanford co-authors are graduate student Christine Peters; postdoctoral scholar James Zengel, PhD; Siyuan Ding, PhD, instructor in medicine gastroenterology & hepatology; basic life research scientist Kuo-Feng Weng, PhD; former visiting research student Kristi Kobluk, DVM; Joshua Elias, PhD, assistant professor of chemical and systems biology; Peter Sarnow, PhD, professor of microbiology and immunology; Harry Greenberg, MD, professor of gastroenterology and hepatology and of microbiology and immunology; and Claude Nagamine, PhD, DVM, associate professor of comparative medicine.

Researchers at the Chan Zuckerberg Biohub and the VA Palo Alto Health Care System also contributed to the work.

Stanfords departments of Microbiology and Immunology and of Biology also supported the work.

Go here to see the original:

In human cells and mice, a cure for the common cold, Stanford-UCSF study reports - Stanford Medical Center Report

Lancet Commission Lists Three Tools for Effectively Zapping Malaria – News18

The Lancet Commission on Malaria Eradication which recently published its report states that eradication of the mosquito-borne disease is possible by 2050. The commission, however, warns that while over 100 countries have managed to eradicate malaria, a chance of resurgence and re-establishment is still possible.

According to the Lancet Commission, in India, the malaria vector, Anopheles stephensi, has a suitable environment for breeding which means incidence of the disease in urban areas is quite high.

Notably, in 2017, there were a total of 219 million malaria cases in 86 countries, a decline from 262 million cases, and 839,000 malaria deaths in 2001. Out of the 219 million cases reported in 2017, 9.6 million were in India.

According to the Lancet commission, three important tools are necessary in the worlds attempt at eliminating malaria by 2050. These include rapid diagnostic tests, artemisinin-based combination therapy, and long lasting insecticide-treated nets.

Apart from these, IT, molecular methods for diagnosis and surveillance, and a new drug for Plasmodium vivax malaria will act as catalysts for eradication as well.

India follows the recommendations of World Health Organization (WHO)'s Global Technical Strategy for Malaria to eradicate the mosquito-borne disease. However, improper waste management, lack of municipal water supply infrastructure, etc, results in breeding facilitation of the Anopheles mosquito.

The out of pocket (OOP) burden, according to the commission is undesirable, forcing families to forego necessary care and causing medical impoverishment.

According to the Commission, India must invest a lot more in making malaria prevention and treatment tools more affordable and accessible for its citizens.

Speaking about the same, Dr Shailja Singh, Associate Professor at Special Centre for Molecular Medicine, JNU, says, that generalised policies will not work in case of India because the nation in itself is so diverse, and so are the Plasmodium parasites that affect its people.

According to her, to achieve complete eradication, firstly, a large scale surveillance to capture the diverse nature of malaria in India is needed. Secondly, a mass campaignlike in the case of poliocan also help in eradication processes.

The Lancet Commission further notes that eradication of the mosquito will not only reduce mortality, but will also be a financial win for nations, as according to a WHO report, it will result in an estimated gain in GDP of USD 238 billion, which would be a lot higher than the cost of eradicating itUSD 35 billion.

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, Telegram, TikTok and on YouTube, and stay in the know with what's happening in the world around you in real time.

More:

Lancet Commission Lists Three Tools for Effectively Zapping Malaria - News18